



HAL
open science

Alternative Splicing of TAF6: Downstream Transcriptome Impacts and Upstream RNA Splice Control Elements

Catherine Kamtchueng, Marie-Eve Stébenne, Aurélie Delannoy, Emmanuelle Wilhelm, Hélène Léger, Arndt G. Benecke, Brendan Bell

► **To cite this version:**

Catherine Kamtchueng, Marie-Eve Stébenne, Aurélie Delannoy, Emmanuelle Wilhelm, Hélène Léger, et al.. Alternative Splicing of TAF6: Downstream Transcriptome Impacts and Upstream RNA Splice Control Elements. PLoS ONE, 2014, 9 (7), pp.e102399. 10.1371/journal.pone.0102399. hal-01365767

HAL Id: hal-01365767

<https://hal.sorbonne-universite.fr/hal-01365767v1>

Submitted on 13 Sep 2016

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution 4.0 International License



Alternative Splicing of TAF6: Downstream Transcriptome Impacts and Upstream RNA Splice Control Elements

Catherine Kamtchueng¹, Marie-Ève Stébenne¹, Aurélie Delannoy¹, Emmanuelle Wilhelm¹, Hélène Léger², Arndt G. Benecke^{2,3}, Brendan Bell^{1*}

1 RNA Group, Département de microbiologie et d'infectiologie, Faculté de médecine et sciences de la santé, Université de Sherbrooke, and Centre de recherche du CHUS, Pavillon de recherche appliquée sur le cancer, 3201 rue Jean-Migneault, Sherbrooke, Québec, Canada, **2** Institut des Hautes Etudes Scientifiques, Centre National de la Recherche Scientifique, 35 route de Chartres, Bures sur Yvette, France, **3** Université Pierre et Marie Curie, UMR8246 CNRS, 7 quai Saint Bernard, Paris, France

Abstract

The TAF6 δ pathway of apoptosis can dictate life versus death decisions independently of the status of p53 tumor suppressor. TAF6 δ is an inducible pro-apoptotic subunit of the general RNA polymerase II (Pol II) transcription factor TFIID. Alternative splice site choice of TAF6 δ has been shown to be a pivotal event in triggering death via the TAF6 δ pathway, yet nothing is currently known about the mechanisms that promote TAF6 δ splicing. Furthermore the transcriptome impact of the gain of function of TAF6 δ versus the loss of function of the major TAF6 α splice form remains undefined. Here we employ comparative microarray analysis to show that TAF6 δ drives a transcriptome profile distinct from that resulting from depletion of TAF6 α . To define the *cis*-acting RNA elements responsible for TAF6 δ alternative splicing we performed a mutational analysis of a TAF6 minigene system. The data point to several new RNA elements that can modulate TAF6 δ and also reveal a role for RNA secondary structure in the selection of TAF6 δ .

Citation: Kamtchueng C, Stébenne M-È, Delannoy A, Wilhelm E, Léger H, et al. (2014) Alternative Splicing of TAF6: Downstream Transcriptome Impacts and Upstream RNA Splice Control Elements. PLoS ONE 9(7): e102399. doi:10.1371/journal.pone.0102399

Editor: Emanuele Buratti, International Centre for Genetic Engineering and Biotechnology, Italy

Received: October 4, 2013; **Accepted:** June 19, 2014; **Published:** July 15, 2014

Copyright: © 2014 Kamtchueng et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by the award of a NSERC Discover Grant to B. Bell. The funding agency website is <http://www.nserc-crsng.gc.ca/>. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* Email: Brendan.Bell@USherbrooke.ca

Introduction

The TAF6 δ pathway of apoptosis (Fig. S1) can control cell death versus life decisions of human cells [1,2,3]. TAF6 δ is a splice variant of the TAF6 protein that is a core subunit of the general RNA polymerase II (Pol II) transcription factor, TFIID [4,5]. TFIID nucleates the formation of the Pol II pre-initiation complex and therefore represents a highly regulated step in the gene expression pathway of protein-coding genes [6]. TFIID is the major core promoter recognition complex of the Pol II machinery and consists of TATA-binding protein (TBP) and a constellation of approximately 14 TBP-associated factors (TAFs) [7]. TAF6 δ is an inducible pro-apoptotic isoform of TAF6 that lacks 10 amino acids in its histone-fold domain. In contrast to the major TAF6 α isoform, TAF6 δ cannot interact with TAF9 and instead forms a TAF9-lacking complex termed TFIID π that drives a pro-apoptotic gene expression [2]. The TAF6 δ pathway has emerged as a model system to investigate the mechanisms that transduce extracellular signals to trigger cellular suicide by impinging on the basal Pol II machinery. Moreover, because the TAF6 δ pathway induces cell death independently of p53 [3], it represents a potential therapeutic target of strategic value for the killing of tumor cells that frequently lack functional p53 [8].

Modified antisense RNA oligonucleotides that force the splicing machinery to switch from producing a majority of TAF6 α to producing a majority of TAF6 δ in living cells trigger apoptosis demonstrating that changes in alternative splicing can trigger the TAF6 δ pathway of programmed cell death [2,3]. Alternative

splicing plays a major role in proteomic diversification [9,10]. In the case of programmed cell death, alternative splicing can control cell life versus death decisions by regulating the balance of anti-apoptotic versus pro-apoptotic splice variants of genes within cell death pathways [11]. *Cis*-acting RNA elements can either enhance or silence the selection of alternative splice sites by the spliceosome to control splice site decisions [12]. These elements are classified upon their effect on a given splicing event and their location. Regulatory *cis*-acting RNA elements thus include exonic splicing enhancers (ESE), exonic splicing silencers (ESS), intronic splicing enhancers (ISE), and intronic splicing silencers (ISS). These *cis*-acting RNA elements act to recruit *trans*-acting protein factors, often from the SR protein family [13] or the hnRNP family [14]. Layered upon the network of RNA-protein interactions that underpin alternative splicing decisions is the key role of RNA secondary structure within the pre-mRNA that has an impact on splice site recognition by the spliceosome as well as on RNA-protein interactions [15,16,17,18].

One important challenge in the study of all alternative splice events is to define the relative biological impact of the gain of the alternative splice form versus the loss of the constitutive form. While the induction of alternative splice variants often have important biological effects, in extreme cases alternative splicing serves only to dampen gene expression, as is the case when these events are coupled to the nonsense-mediated decay pathway [19,20]. To shed light on the mechanism controlling the TAF6 δ pathway of apoptosis, here we have compared the transcriptome impacts of loss of function of the major TAF6 α splice variant via

siRNA depletion versus those resulting from the induction of the pro-apoptotic TAF6 δ splice variant. The results reveal an essential function for TAF6 δ induction in the reprogramming of a specific pro-apoptotic transcriptome landscape. Despite the importance of inducible TAF6 δ expression, nothing is currently known about the mechanisms governing alternative TAF6 δ splicing. We therefore developed and validated a minigene system for the mutational dissection of TAF6 *cis*-acting RNA elements. We report here the first identification of RNA elements that can influence splicing of TAF6 δ .

Materials and Methods

Cell culture

HeLa cell line was maintained in culture in Dulbecco's modified Eagle's medium supplemented with 2.5% fetal calf serum and 2.5% calf serum.

Plasmids

To construct the TAF6 minigene (pTAF6mg), the genomic region of TAF6 containing exon 2 to exon 3 was amplified by PCR from HeLa cell genomic DNA with primers 5'-AAAAAGG-

GATCCCATGGGCATCGCCCAGATTCAGG-3' (forward) and 5'-AAAAAGGAATTCCAAGGCGTAGTCAATGTCAGTGG-3' (reverse). The PCR product was ligated into pTZ57R/T (Fermentas). The new plasmid was digested with EcoRI and BamHI and the TAF6 fragment was inserted into the same sites of pcDNA3.1+. The mutated minigenes were created by PCR mutagenesis using Pfu DNA polymerase with specific primers bearing mutations [21] (all sequences of oligonucleotides used in this study are listed in Table S1).

Transfections

Dicer substrate (dsi) RNA 5'-rGrGrArGrUrGrUrCrCrArGrArArGrUrArCrArUrCrGrUrGGT-3' (T6-1) and 5'-rCrGrCrUrArArGrCrGrGrArArGrGrArGrUrUrArGAT-3' (T6-2) were employed to deplete all known splice variants of TAF6. dsRNA were transfected at a final concentration of 10 nM with lipofectamine 2000 (Invitrogen) as a delivery agent (1.6 μ l/ml) according to the manufacturer's recommendations. 250 to 300 ng of wild-type or mutant TAF6 minigene were transfected with 1 μ l DMRIE-C (Invitrogen) per well in 24 well plate according to the manufacturer's recommendations. Cells were transfected by dsRNA T6-1 two times. The second transfection was performed 24 h after the first




Figure 1. TAF6 is essential for human cell viability. (A) PCR analysis of TAF6 mRNA levels 72 hours post-transfection with siRNAs targeting all TAF6 mRNAs. (B) Total cell extracts from HeLa cells transfected with the indicated siRNAs for 72 hours were separated by SDS-PAGE subject to Western blot analysis with monoclonal antibodies specific for TAF6 α and tubulin as a loading control. (C) The viability of HeLa cells transfected with siRNA directed against TAF6 was measured 4 days post-transfection by methylene blue staining (see materials and methods). Viability (y-axis) is expressed relative to that of cells transfected with control siRNA. (D) TAF6 depletion results in loss of HeLa cell viability. HeLa cells were treated for 4 days with control siRNA (panel 1), or siRNA that target the TAF6 mRNA (panels 2 & 3). Cells were photographed with a phase-contrast microscope. doi:10.1371/journal.pone.0102399.g001




Figure 2. Distinct impact of TAF6 δ induction versus total TAF6 mRNA depletion on the transcriptome of HeLa cells. (A) Heat map showing the impact of statistically significantly ($p < 0.05$) changes in gene expression during TAF6 mRNA depletion by siRNA at 48 and 72 hours post transfection. Red indicates induction and blue repression. Genes were ordered according to fold change at 72 hours post transfection. (B) Distribution of expression profiles amongst the six possible outcomes. Genes upregulated or downregulated at the both time points are schematized with lines. (C) The previously defined TAF6 δ transcriptome signature compared to the transcriptome resulting from depletion of total TAF6 mRNA. The heat map shows the gene expression during siRNA-mediated total TAF6 mRNA depletion for the 961 TAF6 δ signature genes. (D) Venn diagrams depicting genes subsets statistically significantly regulated by total TAF6 mRNA depletion versus by TAF6 δ induction. Upper diagram contains all regulated genes, middle diagram includes induces genes (upward arrow) and the lower Venn diagram includes repressed genes (downward arrow). (E) Gene ontology analysis of statistically significantly regulated genes during total TAF6 mRNA depletion. Enriched pathways are shown with their associated p-values.

doi:10.1371/journal.pone.0102399.g002

one and culture was maintained for a total of 48 or 72 h before harvesting cells for RNA extraction (RNeasy Qiagen) for microarray analysis or 64 h for protein analysis. All transfections were performed with OptiMEM medium (Invitrogen). Each transfection experiment was repeated three times.

Viability assay by methylene blue staining

HeLa cells were split in 24 well plates at a concentration of 75 000 cells/well and transfected 12 hours later with 10 nM dsRNA combined with lipofectamine 2000 (Invitrogen) as recommended by the supplier. dsRNA were transfected again 24 and 48 h after the first transfection. The culture was maintained for a total of 4 days after the first transfection. The culture medium was removed and the cell monolayer was washed carefully with 500 μ l PBS. Cells were stained for 30 min at RT by the addition of 200 μ l of a solution containing 5 mg/ml of methylene blue in 50% ethanol. The plate was carefully and extensively washed with water until no blue stain remained in the water. The plate was air dried completely. 500 μ l of a PBS solution containing 10 mg/ml N-lauroyl sarcosine (Sigma L-5125) was added to each well. Lysis was performed for 1 h at RT. 100 μ l of each lysate was used to measure absorbance at 595 nm

(A515 nm = control), corresponding to methylene blue incorporation and cell content.

RT-PCR

Total RNA was extracted from cells using Trizol (Invitrogen) according to the manufacturer's recommendations. RNA was treated with 1 unit of DNase I (Promega) for 30 minutes at 37°C to remove any contaminating DNA. 1 μ g of total RNA was reverse transcribed using MMuLV reverse transcriptase. Specific oligonucleotides for endogenous TAF6 (forward 5'-ATGGG-CATCGCCAGATTCAGG-3' and reverse 5'-AAGGCG-TAGTCAATGTCCTGG-3') and exogenous TAF6 minigene constructs (forward 5'-ATGGGCATCGCCAGATTCAGG-3' and reverse 5'-AATAGCGATCCACGCGACTAGTGG-3') were used for PCR amplification of 1/10 of the total cDNA (25 cycles, 1 min at 94°C, 45 sec at 58°C, 50 sec at 68°C, initial step 3 min at 95°C, final extension 5 min at 68°C), using Taq DNA polymerase. The splicing isoforms were quantified by capillary electrophoresis on a BioAnalyser 2100 (Agilent) according to the manufacturer's instructions.





Figure 3. Development and validation of a minigene system to study the alternative splicing of TAF6. (A) A schematic diagram showing the workflow used to study *cis*-acting RNA sequences in TAF6 alternative splicing using a TAF6 minigene plasmid. The plasmid containing an uninterrupted genomic sequence from the *taf6* gene that includes portions of exons 2 and 3, as well as the natural intron 2 is depicted along with the positions of primers used to detect exogenously expressed RNA species by RT-PCR. Minigenes were transfected into HeLa and 42 hours later total RNA was isolated for use in RT-PCR with primers from flanking plasmid sequences. PCR products were quantified by analysis using an Agilent Bioanalyser. The percentage TAF6 δ is expressed as a ratio of total spliced TAF6 mRNAs ($\delta + \alpha$). (B) Validation of the minigene system via mutagenesis. The proximal (P) 5' splice site (SS) and distal (D) 5' SS are illustrated. Mutations that knock-out (ko) SS or strengthen by creating consensus (cons) SS and their impact on the percentage of TAF6 δ produced (x-axis), are indicated. ($P < 0.05 = *$; $P < 0.01 = **$; $P < 0.001 = ***$). doi:10.1371/journal.pone.0102399.g003

A



B




Figure 4. Scanning mutagenesis of constitutive exon 2 and exon 3. (A) Scanning mutations (black rectangles) in the TAF6 minigene were generated by PCR before transfection into HeLa. RNA was isolated and splice products were analysed by RT-PCR as in Figure 3. The percentage of exogenous TAF6 δ mRNA produced by a given mutated construct are graphically shown (x-axis). (B) As in panel A, except that mutations were in exon 3. ($P < 0.05 = *$; $P < 0.01 = **$; $P < 0.001 = ***$). doi:10.1371/journal.pone.0102399.g004

Western blot analysis

After treatment as described, cells were lysed in $1.5 \times$ laemmli sample buffer, sonicated and electrophoresed on 7.5 and 12% SDS-PAGE before electro-transfer to PVDF membrane. Blots were probed with previously described antibodies against TAF6 α , TAF6 δ or TBP [1] followed by goat anti-mouse HRP-conjugate secondary antibodies (Jackson Immunoresearch Laboratories) before enhanced chemiluminescence detection. Mouse monoclonal antibodies that detect total TAF6 proteins levels were from BD transduction laboratories #610304.

Microarrays

RNA isolation and quality control were performed as previously described [2,22] from cells treated with siRNA T6-1. Applied Biosystems HGS V2 arrays [23] were hybridized, washed, and exposed according to the protocols of the technology provider. Raw data were quality controlled [24], and normalized using NeONORM (k-parameter = 0.2) [25]. Longitudinal analysis was performed using a Kohonen-maps based classifier as described in [26], using the CDS statistical test [27]. The data are freely accessible through the MACE database at <http://mace.ihes.fr> under accession no. (maceid): 2732656872.

Results

SiRNA-mediated depletion of TAF6 causes a loss of viability in human cells

We have previously analyzed the transcriptome impact of the induction of TAF6 δ by using microarray experiments [2]. To define the impact of the loss of total TAF6 protein in human cells we performed transcriptome-wide analysis of gene expression following depletion of total TAF6 proteins by siRNA. Importantly, the minor TAF6 δ protein isoform is not expressed at detectable levels in HeLa cells under normal growth conditions, so that the effects of the siRNA cannot be due to significant reductions in TAF6 δ protein levels [2,3] (see also Fig. S2). siRNAs were designed and validated for their ability to reduce TAF6 protein levels. Two siRNAs resulted in reduction of TAF6 mRNA levels (Fig. 1A) and protein levels (Fig. 1B). Quantification of TAF6 α protein levels from three independent experiments using the ImageJ software package (<http://rsbweb.nih.gov/ij/>) indicated that si1 and si2 typically reduced TAF6 α protein levels by 70–80% and 40–60%, respectively. To determine the impact of the loss of total TAF6 protein on cell viability we employed the methylene blue colorimetric assay (see materials and methods). Both siRNAs that depleted TAF6 resulted in a concomitant loss of cell viability (Fig. 1C–D). We conclude that TAF6 expression is essential for cell viability in human cells, extending previous results demonstrating that TAF6 is essential for viability in distinct organisms including *S. cerevisiae* [28,29], *Drosophila* [30] and zebrafish [31]. We next used si1, the siRNA that most efficiently reduced total TAF6 expression and resulted in the highest loss of viability, to further determine the impact of knock-down of TAF6 on the transcriptome using microarray analysis. Total RNA was isolated from HeLa cells treated with siRNA directed against TAF6 and from cells treated with control siRNA for microarray analysis [2,22,32]. Two time points (48 and 72 hours) were chosen for transcriptome analysis to ensure the detection of the broadest possible number of

TAF6-dependent transcripts as well as to ensure measurements before the onset of massive cell death. The levels of TAF6 mRNA were internally controlled in the transcriptome analysis by probes for *taf6* and showed at least 80% reduction at both 48 and 72 hours post-transfection (data not shown).

Distinct transcriptome impacts of depleting TAF6 α versus inducing TAF6 δ

The knock-down of total TAF6 resulted in statistically significant changes in gene expression levels including a global reduction in transcription accompanied by the increase in a minority of mRNA transcripts 48 hours after siRNA transfection and particularly after 72 hours (Fig. 2A). Since siRNA can potentially have off-target effects, we sought to validate the specificity of the siRNA used by comparing the expression of a panel of genes with an independent siRNA directed against TAF6. The genes assayed showed comparable changes in response to treatment with both the most efficient siRNA, si1 and the less efficient siRNA, si2 (Fig. S3). These data are compatible with the interpretation that the gene expression measured by microarray is due largely to specific interference with TAF6 expression. We also compared the changes in gene expression of the 961 previously identified TAF6 δ -dependent transcripts [2] to changes in response to siRNA depletion of total TAF6 and found that the two conditions result in distinct transcriptome landscapes (Fig. 2C). To examine more closely the changes resulting from the induction of TAF6 δ versus depletion of TAF6, we filtered the microarray data to compare the overlap between the two sets of regulated transcripts. Of 961 TAF6 δ -dependent transcripts 128 were also significantly regulated by the siRNA against TAF6 at either 48 or 72 hours (Fig. 2D). Of the 128 regulated transcripts the majority (81) were oppositely regulated (induction versus repression). 44 transcripts were induced by both the loss of TAF6 and the induction of TAF6 δ , and the overlap between these genes was statistically significant ($P = 1.05 \times 10^{-09}$, hypergeometric distribution). In contrast, 1513 genes were repressed in the absence of TAF6 and only three transcripts were repressed in both conditions (Fig. 2D) and there was no statistically significant overlap between repressed genes. The microarray results revealed a minor subset of common effects in the induction of TAF6 δ versus depletion of total TAF6 transcripts. Importantly, the data also reveal that the induction of TAF6 δ drives a distinct pro-apoptotic gene expression program and therefore underscore the necessity for TAF6 δ isoform expression to trigger this specific pathway of apoptosis. To further explore the effects of TAF6 depletion gene ontology analysis was applied. Of the seven pathways that are statistically overrepresented during TAF6 depletion, only three including the integrin signaling pathway, the p53 pathway and apoptosis signaling pathways were also found in the TAF6 δ transcriptome signature (Fig. 2E) [2]. To extent the comparison of gene expression patterns we compared the loss of total TAF6 at the earlier time point of 48 hours of treatment with siRNA, since these changes could potentially represent direct TAF6 target genes, with the gain of TAF6 δ (Fig. S4). The data reinforce the distinct impact of TAF6 δ induction compared to loss of TAF6 (Fig. S4). Taken altogether, the microarray data underscore the fact that the simple loss of total TAF6 mRNA does not recapitulate the same



A**B**

Figure 5. Targeted mutagenesis of intron 2 of the *taf6* gene. (A) Mutations of intron motifs are indicated with arrows in the TAF6 minigene constructs. HeLa cell transfection and splice product analysis was carried out as in Figure 3. The percentage of exogenous TAF6 δ mRNA is graphically shown (x-axis). (B) As in panel A except mutations were focused on poly G motifs found within intron 2. ($P < 0.05 = *$; $P < 0.01 = **$; $P < 0.001 = ***$). doi:10.1371/journal.pone.0102399.g005




Figure 6. RNA secondary structure at the proximal 5' splice site can force the selection of TAF6 δ . (A) The sequence and names of mutations within alternative exon 2 (2a) of the TAF6 minigene constructs are indicated at the left. A potential SF2/ASF binding site is indicated by a blue box. HeLa cell transfection and splice product analysis was carried out as in Figure 3. The percentage of exogenous TAF6 δ mRNA is graphically shown (x-axis). (B) As in panel A except that mutations (red nucleotides) are shown to the right in hypothetical RNA secondary structures generated using the M-Fold algorithm. The proximal 5' splice site (SS) is indicated as green boxes. (C) As in B with further mutations. (D) As in B with further mutations. ($P < 0.05 = *$; $P < 0.01 = **$; $P < 0.001 = ***$). doi:10.1371/journal.pone.0102399.g006

transcriptome impact that is observed when splicing of TAF6 δ is selected at the expense of TAF6 α expression.

Development and validation of a minigene system to study TAF6 alternative splicing

Having established the importance of the induction of TAF6 δ versus the loss of TAF6 α in driving a specific transcriptome profile and cell death programme, we next sought to investigate the molecular mechanisms that control the expression of the minor TAF6 δ splice variant versus the major TAF6 α splice variant. We cloned the genomic region from the TAF6 gene that contains part of exon 2, the alternative portion of exon 2, the natural full-length intron 2, and a part of exon 3 into the eukaryotic expression pcDNA3.1+ under the control of the CMV promoter (Fig. 3A). No deletions, truncations or other modifications to the short (99 nucleotides) intron were performed so that it retains the full-length endogenous sequence. HeLa cells were chosen as a model to study TAF6 alternative splicing since the pro-apoptotic TAF6 δ splice variant was originally cloned from a HeLa cell cDNA library [1]. PCR primers specific to the transcribed flanking vector sequences were used to amplify exogenous TAF6 transcripts after transient transfection of the minigene into HeLa cells (Fig. 3A). PCR products corresponding to the expected sizes for the minigene products of unspliced pre-messenger, the major TAF6 α transcript, and the minor TAF6 δ transcript were detected by RT-PCR (Fig. 3A). Sequencing of each of these PCR products showed that they corresponded exactly to the expected splice products (B.B., unpublished results). Importantly, the ratio of TAF6 δ versus total transcripts was found to range from 10% to 20% between independent transfections (Figs. 3B, 4A and 4B), a percentage that corresponds well to the endogenous TAF6 splicing pattern in HeLa cells [3]. The growth conditions of independent transfections appeared to influence basal levels of TAF6 δ since biological triplicates within a single wave of transfections were highly reproducible (Figs. 3–7). Taken together, these data indicate that the plasmid minigene system accurately recapitulates endogenous TAF6 δ splicing patterns in transfected HeLa cells.

To further characterize the minigene system we tested constructs bearing point mutations within one of the two alternative 5' splice sites (SSs). When we crippled the proximal (α) 5' SS by mutating the first two nucleotides of the intronic SS from the consensus GT to CA, the transfected minigene spliced uniquely at the alternative distal (δ) 5' SS, as expected (Fig. 3B, Pko). Likewise, the same crippling mutation of the distal (δ) 5' SS resulted in splicing in HeLa cells uniquely at the proximal (α) 5' SS (Fig. 3B, Dko). We used a web tool http://rulai.cshl.edu/new_alt_exon_db2/HTML/score.html provided by Zhang laboratory (Cold Spring Harbor Laboratories) to calculate the alternative distal 5' SS and the constitutive proximal 5' SS strength scores as 2.8 and 6.4 respectively. These are relatively weak given that a perfect consensus site score is 12.6 and the average value for a constitutive 5' SS is 8.1. To test the impact of splice site strength we mutated both sites individually to the consensus (AG/GUAAGU). When the proximal 5' SS is changed to the consensus no residual detection of the alternative δ variant was detected (Fig. 3B, Pcons). When the alternative distal 5' SS

was changed to a consensus sequence all of the splice products used the distal site (Fig. 3B, Dcons). We conclude that one parameter that impacts the alternative splice site choice of TAF6 is the complementarity of the 5' SSs to U1 snRNP as expected. We further conclude that the minigene system we developed provides a useful system to dissect the *cis*-acting RNA elements that control the expression of TAF6 δ .

Having established a minigene system to study TAF6 alternative splicing we next set out to perform a mutational dissection of the RNA elements within the minigene that impact the expression of the pro-apoptotic TAF6 δ isoform. We have applied a combination of resources to guide our mutational analysis including predictive algorithms for RNA binding proteins and *cis*-acting elements including RESCUE-ESE [33], ESE finder [34], and “Splicing Rainbow” [35]. We also considered evolutionary conservation of intronic sequences and employed scanning mutagenesis to identify *cis*-acting RNA splicing elements. For simplicity we have subdivided the minigene into several sub-regions and our mutational analysis of each region is presented below.

Scanning mutagenesis of constitutive exon 2 and exon 3


To search for *cis*-acting RNA elements we initially performed scanning by mutating blocks of 10 nucleotides within the constitutive portion of exon 2 (Fig. 4A). The mutation of two nucleotide blocks Exon 2-1 and Exon 2-3 had no significant effect on the TAF6 splicing pattern (Fig. 4A). Another nucleotide block in exon 2, exon 2-2 produced reproducible reductions in the levels of TAF6 δ (Fig. 4A). These results evoke that a possible *cis*-acting RNA sequence within the exon 2-2 could favour the selection of the distal (δ) 5' SS. We note that in HeLa cells the endogenous basal levels (\sim 10%) of TAF6 δ do not produce detectable TAF6 δ protein by Western blotting or immunofluorescence with sensitive antibodies, suggesting the exon 2-2 mutation would not be expected to have profound biological impacts.

We next used the same scanning mutagenesis to query whether exon 3 contained RNA elements important for the selection of TAF6 δ . We mutated three 10 nucleotide blocks near the 3' SS of our TAF6 minigene (Fig. 4B). We found no significant differences in the ratio of TAF6 δ for any of the three mutations exon 3-1, 3-2 or 3-3 (Fig. 4B). We conclude that the region of exon 3 proximal to intron 2 does not play a major role in the selection of the TAF6 δ splice variant.


Targeted mutagenesis of intron 2 of the *taf6* gene

To begin characterizing intron 2 of the minigene, we first examined sequence homology between the ninety-nine nucleotide long natural human intron 2 and forty-six vertebrate species (<http://genome.ucsc.edu/>). Minimal informative sequence conservation was found within intron 2, however a small conserved motif that fits the degenerate γ UnAy consensus [36] for a human branch point site was identified at nucleotides 153–157 (Fig. S5). To determine if the adenine at position 156 corresponds to the branchpoint we mutated it to a guanosine. Upon transfection in HeLa cells the mutated minigene showed profoundly reduced splicing activity (Fig. S6). The residual splicing activity is low but detectable and could represent the inefficient use of alternative

A



B



C




Figure 7. Evidence for an exonic splicing silencer in alternative exon 2. (A) A hypothetical RNA structure generated by M-fold is illustrated along with the position of the proximal TAF6 5' splice site (green box). Selected mutations are indicated with arrows (red text) (B) The names of mutations within alternative exon 2 (2a) of the TAF6 minigene constructs are indicated at the right. HeLa cell transfection and splice product analysis was carried out as in Figure 3. The percentage of exogenous TAF6 δ mRNA is graphically shown (x-axis). Mutations (red nucleotides) are shown to the right in hypothetical RNA secondary structures generated using the M-Fold algorithm. (C) As in panel A except that mutations (red nucleotides) are shown to the left. ($P < 0.05 = *$; $P < 0.01 = **$; $P < 0.001 = ***$). doi:10.1371/journal.pone.0102399.g007

neighboring adenines. We conclude that adenine 156 is essential for splicing of the TAF6 minigene and most likely represents the major branchpoint site in intron 2.

To further explore *cis*-acting RNA elements within intron 2 that could impact the selection of the distal 5' SS, we chose candidate motifs after manual and software-assisted (see above) analysis of potential regulatory sequence motifs. We decided to test the roles of several sequence motifs in the TAF6 minigene system including poly C motifs [37], poly G motifs [38] and a potential binding site for hnRNPA1 [39] because these motifs have been previously shown to influence alternative splicing. The mutation of a potential hnRNPA1 binding site [40] within intron had no significant effect on the TAF6 splicing pattern (Fig. 5A, koA1). Likewise, a mutation of the CCCC (C_4) motif at position 175–178 had little effect on TAF6 alternative splicing (Fig. 5A, C_4 -175). The mutation of a C_3 motif at positions 125–127 and C_4 combined significantly reduced levels of the TAF6 δ splice variant (Fig. 5A, C_3 -125; C_4 -132). To determine if one of these motifs was more important for TAF6 δ expression we mutated them individually and found that mutation of C_3 -125 alone caused a small but measurable reduction in TAF6 δ levels (Fig. 5A, C_3 -125). Mutation of the C_4 -132 motif alone caused a reduction in TAF6 δ expression similar to that of the double mutation (Fig. 5B, C_4 -132), suggesting that the C_4 -132 motif plays the predominant role in TAF6 δ splice site selection. To complete our investigation of poly C motifs, we mutated a C_3 motif at position 91–93 in the minigene and found it produced modestly reduced splice selection of TAF6 δ (Fig. 5A, C_3 -91).

We next turned our attention to the potential function of three poly G sequences within intron 2 of the TAF6 minigene. The mutation of a G_3 motif at position 113–115 resulted in reduced expression of the TAF6 δ splice variant (Fig. 5B, G_3 -113). The mutation of a G_3 motif at position 129–131 had little impact on TAF6 splicing ratios (Fig. 5B, G_3 -129). The mutation of a G_3 motif at position 150–152 generated wild type splicing ratios. (Fig. 5B, G_3 -150). Taken together, our analysis of intron 2 of the TAF6 minigene define a putative branchpoint adenosine at position 156 that is essential for splicing, and shows that specific poly C and poly G motifs in the intron can enhance the selection of the pro-apoptotic TAF6 δ splice form.

RNA secondary structure at the proximal 5' splice site can force the selection of TAF6 δ

We then focused on the alternative exon 2 (exon 2a) a critical region of the minigene because it lies physically between the α and δ alternative 5' splice sites (Fig. 3A), and because modified antisense RNA oligonucleotides that anneal to it can shift the splicing from the major to the pro-apoptotic δ form in living cells [3]. The ESEfinder algorithm [34] was employed and detected a potential SF2 binding site in exon 2a (Fig. 6A). To test a potential role for the SF2 motif in the 5' splice site choice we designed two point mutations to prevent (Fig. 6A, SF2-) or enhance (Fig. 6A, SF2+) SF2 binding. Upon transfection these mutations both gave strong increases in the levels of the δ splice form (Fig. 6A), a result not compatible with a role for SF2 binding to this motif. To further dissect the impact of the two-nucleotide mutation within

SF2+ that caused a complete reversal of the splicing pattern, we mutated these positions individually. Mutation of position 68 alone had little effect on the splicing pattern (Fig. 6A, A68C). In contrast, mutation of adenosine 73 to guanosine alone resulted in a complete shift towards the usage of the distal δ 5' SS (Fig. 6A, A73G). Having ruled out a role for SF2, we sought an alternative hypothesis for the strong impact of this mutation. Given the well-documented importance of RNA secondary structure on alternative splicing [15,17,18,41], we employed the M-Fold algorithm [42] to test for potential impacts on RNA structure. When compared to the wild type sequence the A73G mutation was predicted to form a stem-loop that based on precedence [43] would be stable enough to potentially block U1 snRNP from binding to the proximal 5' splice site (Fig. 6A, right). To test the hypothesis that mutation A73G reverses TAF6 splicing via the formation of secondary structure we performed further mutagenesis to provide support for the putative G73 - C86 base pair in cells. Mutation of C86U in the wild type context A73 did not change TAF6 splicing pattern (Fig. 6B). We also performed mutations that are predicted to form a stem-loop of equal stability to A73G replacing the natural C86 within position 5 of the proximal 5' splice site with G to increase its strength. This construct showed less δ splicing than the wild type (Fig. 6B mutant A73C-C86U), compatible with a competition between splice site strength and RNA secondary structure in cells. To test whether the potential weak secondary structure formed by the wild type sequence could impact basal TAF6 splicing ratios we performed a series of mutations that would weaken such a potential structure, but found no strict correlation between the stability of such a structure and splice site selection (Fig. 6C). We conclude that any secondary structure forming with the wild type pre-mRNA under normal cellular conditions is not strong enough to impact selection of the distal 5' SS. To further confirm the putative structure formed by the A73G mutation we performed mutations that disrupt the structure while leaving the proximal 5' SS untouched and found no change in splicing (Fig. 6D, GC 74). Mutations that weaken but do not ablate the putative A73G-induced stem-loop showed intermediate levels of distal 5' SS usage (Fig. 6D, GC 75 & GC 76). A point mutation in the loop of the predicted stem-loop had no effect, as expected (Fig. 6D, GC 78). Taken collectively, these findings indicate that a stem-loop structure competing for the proximal 5' SS can strongly enhance the use of the distal δ 5' SS.

Evidence for an exonic splicing silencer in alternative exon 2

Given that local secondary structure occurs at the proximal 5' SS, and that it is located only 30 nucleotides from the distal 5' SS, we postulated that competition between RNA structure and the distal 5' SS might also play a role in the expression of TAF6 δ . We used the M-Fold algorithm [42] to predict potential secondary structures overlapping the distal 5' SS. The most probable theoretical stem-loop structure predicted could potentially occlude the interaction of U1 snRNP interaction with the distal δ 5' SS (Fig. 7A). To provide evidence to confirm or exclude the existence of such a stem-loop we constructed a series of minigenes with mutations that would weaken, destroy or maintain it. No



A**B**

Figure 8. A hypothetical model for TAF6 δ alternative splicing. (A) The TAF6 minigene construct is schematically shown with putative exonic splicing enhancer (ESE), exonic splicing silencer (ESS) and intronic splicing enhancer (ISE) motifs indicated with boxes. Enhancer or silencer definitions are given with respect to the pro-apoptotic TAF6 δ isoform but likely act simultaneously to repress one 5' SS while enhancing the other because of the small distance (30 nucleotides) between them. (B) As in panel A, except that mutations were focused on poly G motifs found within intron 2. doi:10.1371/journal.pone.0102399.g008

correlation was observed between potential stem-loop strength and the splicing outcome, ruling out a major role for such a structure in the regulation of TAF6 alternative splicing (Fig. 7A).

Interestingly, however, our mutational analysis revealed that a single nucleotide change (C66U) produced a greater than two-fold increase in the production of the TAF6 δ splice form (Fig. 7A and B, C66U). To further delineate the role of cytosine 66 we mutated it to uridine, adenosine and guanosine respectively. Mutations C66U and C66A both resulted in clear increases in TAF6 δ splice form production (Fig. 7C), even though these nucleotides have distinct hydrogen bonding specificities within RNA secondary structures. C66G had much less effect than these mutations, although the mutation would also be expected to have altered base-pairing within RNA structure. To further dissect a potential regulatory RNA sequence in the region of cytosine 66 we performed further point mutations. Changing adenosine 67 to thymine significantly increased TAF6 δ splice selection (Fig. 7C, A67T). A nearby change, G70T, also increased TAF6 δ splice selection (Fig. 7C). In contrast, a slightly more distant mutation C60G did not significantly change the splicing ratio (Fig. 7C). Taken together, the above results suggest that an exonic splicing silencer (ESS) is located in the region of nucleotides 66–70 within the alternative exon of TAF6. We found no evidence that RNA secondary structure within this region plays an important role in splice site choice. The mutational data described above support a hypothetical model for *cis*-acting RNA elements in the regulation of TAF6 alternative splicing that is presented schematically in Figure 8.

Discussion

TAF6 is a core subunit of the general RNA Pol II transcription factor TFIID [5], and has previously demonstrated to be essential for viability in several organisms including the budding yeast *Saccharomyces cerevisiae* [28,44], *Drosophila* fruit flies [30], the flowering plant *Arabidopsis thaliana* as well as the fresh water fish *Danio rerio* [31]. Here we show for the first time that TAF6 is essential for viability in human cells (Fig. 1). Although this result is not unexpected, the significance of the finding derives from the potential of TAF6 as a therapeutic target for numerous diseases that result from deregulated apoptosis [45]. Many apoptotic genes are required for normal development at the organismal level but tumor suppressors such as BRCA1, PTEN, CDKN2A (ARF/p16INK4), RB1, APC, and p53, Bcl-2 family members, the caspases and death receptors are all dispensable for viability at the cellular level [46,47]. TAF6 therefore represents a rare class of genes that are essential for cell viability, but also possess splice variants with potent pro-apoptotic activity. As an essential gene with pro-apoptotic potential TAF6 is of high strategic interest in the development of anti-cancer treatments that avoid the development of chemoresistance and to target p53 negative tumors [48].

Using a minigene system that recapitulates the endogenous TAF6 splicing pattern we identified several *cis*-RNA elements that modulate TAF6 δ splicing as schematically shown in Figure 8. The sensitivity of the proximal 5' splice site evokes the possibility that the modulation of RNA folding could contribute to the physiological selection of TAF6 δ . Further work will be required to confirm or exclude this hypothesis. The first mapping of the *cis*-acting RNA within elements provides the essential groundwork for future studies to identify *trans*-acting factors that regulate TAF6 δ splicing. Indeed, the identification of the important RNA elements will be crucial for both proteomic [49] and genomic [50] approaches to identify *trans*-acting splice regulatory proteins. A limitation of the current study is the fact that the mutations could conceivably differentially alter RNA stability in addition to splice site choice. In addition potential long-range *cis*-acting RNA

elements will not have been identified due to the limited size of our TAF6 minigene. Further work will be required to address these possibilities.

Accumulating evidence points to a potential link between the TAF6 δ pathway and cancer biology. A cDNA encoding the major TAF6 α variant was identified in a large-scale screen as being able to increase colony formation in human hepatocellular carcinoma cells and mouse embryonic fibroblasts [51]. Integrative genomic data show that the *taf6* gene is amplified in lung cancer [52]. TAF6 has been reported as a genomic marker of poor prognosis in lung adenocarcinoma [53]. TAF6 mRNA was identified as being overexpressed in inflammatory breast cancer [54]. Interestingly, a specific splice variant of TAF6 with an extended exon 2 is reportedly overrepresented in ductal cell carcinoma [55]. Taken together these findings suggest that the major anti-apoptotic TAF6 α splice variant possesses oncogenic potential. In stark contrast, the minor TAF6 δ splice variant has pro-apoptotic activity evoking a potential tumor suppressor activity [1,2,3]. It is conceivable that anti-apoptotic TAF6 α expression can be decoupled from pro-apoptotic TAF6 δ in certain tumor types. The mapping of key *cis*-acting RNA elements we present here paves the way to experimentally test the existence of mutations in the essential *taf6* gene that could reduce or prevent TAF6 δ expression in human tumors.

Supporting Information

Figure S1 The role of alternative splicing in the TAF6 δ pathway of apoptosis. A schematic model depicts the exon 2, intron 2, exon 3 region of the *taf6* gene. Use of proximal 5' splice site (SS) generates the major TAF6 α isoform that dimerizes with its normal partner TAF9 within the TFIID complex resulting in a gene expression program allowing cell growth. Selection of the distal alternative 5' SS removes 10 amino acids to generate TAF6 δ that cannot interact with TAF9 but is incorporated into a TFIID π complex that drives a pro-apoptotic gene expression and consequently cell death. (TIF)

Figure S2 Endogenous TAF6 δ is not detectable in HeLa cells under normal growth conditions. (A) Protein samples from HeLa cells that were transfected with a scrambled (Ctl), TAF6-1 (si1) or TAF6-2 (si2) siRNA were used to perform western blots. The resulting membranes were incubated with either a TAF6 α or a TAF6 total targeting antibody. (B) The TAF6 α and TAF6 δ specific antibodies were used to detect the protein in lysates of untransfected HeLa cells (NT). Protein extracts of mock (M), empty vector (EV), TAF6 δ (δ) of TAF6 α (α) transfected cells were used as controls. (C) Overexposure of membranes incubated with two different TAF6 δ antibodies show no signal in the untransfected cells. The 37TA 2D5 antibody, which was raised against the δ isoform, but also recognizes TAF6 α , detects no protein in non-transfected cells. The 37TA 1C2 antibody is highly specific for TAF6 δ . The white asterisk indicates a non-specific band that migrates slightly slower than the δ splice variant. (TIF)

Figure S3 Validation of TAF6 siRNA specificity. Quantitative real-time PCR was used to assess the similarity of gene regulation 48 h after the transfection by two different siRNAs targeting TAF6. (TIF)

Figure S4 Distinct impact of TAF6 δ induction versus total early (48 hour) TAF6 mRNA depletion on the transcriptome of HeLa cells. (A) Heat map comparing the impact of statistically

significantly ($p < 0.05$) changes in gene expression during TAF6 mRNA depletion by siRNA at 48 hours post transfection to the TAF6 δ expression profile. Red indicates induction and blue repression. Genes were ordered independently according to fold change. (B) Gene ontology analysis of statistically significantly regulated genes during total TAF6 mRNA depletion at 48 hours post-transfection. Enriched pathways are shown with their associated p-values. (C) Venn diagram depicting genes statistically significantly regulated by total TAF6 mRNA depletion versus TAF6 δ induction. (D) Logarithmic fold-changes of genes regulated statistically significantly by TAF6 mRNA depletion 48 hours post-transfection and by TAF6 δ induction are shown side by side. (TIF)

Figure S5 Schematic representation of mutations used in this study. (A) The TAF6 minigene construct is shown schematically. (B) A nucleotide resolution list of mutations (altered nucleotides shown in red) from different regions of the minigene are illustrated. Black text corresponds to wild type sequences and the exons 2 and 3 (white boxes), alternative exon 2a (grey box) and intron 2 (black line) are indicated above the sequences. (TIF)

Figure S6 Mapping of the branchpoint in intron 2 of the TAF6 minigene. (A) A TAF6 minigene construct bearing a point mutation in a putative branchpoint (adenine 156 to guanosine) was transfected into HeLa cells for splicing analysis as in Figure 3.

References

- Bell B, Scheer E, Tora L (2001) Identification of hTAF(II)80 delta links apoptotic signaling pathways to transcription factor TFIID function. *Mol Cell* 8: 591–600.
- Wilhelm E, Kornete M, Targat B, Vigneault-Edwards J, Frontini M, et al. (2010) TAF6 δ orchestrates an apoptotic transcriptome profile and interacts functionally with p53. *BMC molecular biology* 11: 10.
- Wilhelm E, Pellay FX, Benecke A, Bell B (2008) TAF6 δ controls apoptosis and gene expression in the absence of p53. *PLoS ONE* 3: e2721.
- Bieniossek C, Papai G, Schaffitzel C, Garzoni F, Chaillet M, et al. (2013) The architecture of human general transcription factor TFIID core complex. *Nature*.
- Wright KJ, Marr MT 2nd, Tjian R (2006) TAF4 nucleates a core subcomplex of TFIID and mediates activated transcription from a TATA-less promoter. *Proc Natl Acad Sci U S A* 103: 12347–12352.
- Burley SK, Roeder RG (1996) Biochemistry and structural biology of transcription factor IID (TFIID). *Annu Rev Biochem* 65: 769–799.
- Cler E, Papai G, Schultz P, Davidson I (2009) Recent advances in understanding the structure and function of general transcription factor TFIID. *Cellular and molecular life sciences: CMLS* 66: 2123–2134.
- Vousden KH, Lane DP (2007) p53 in health and disease. *Nat Rev Mol Cell Biol* 8: 275–283.
- Pan Q, Shai O, Lee LJ, Frey BJ, Blencowe BJ (2008) Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. *Nature genetics* 40: 1413–1415.
- Wang ET, Sandberg R, Luo S, Khrebtkova I, Zhang L, et al. (2008) Alternative isoform regulation in human tissue transcriptomes. *Nature* 456: 470–476.
- Schwerk C, Schulze-Osthoff K (2005) Regulation of apoptosis by alternative pre-mRNA splicing. *Mol Cell* 19: 1–13.
- Chen M, Manley JL (2009) Mechanisms of alternative splicing regulation: insights from molecular and genomics approaches. *Nature reviews Molecular cell biology* 10: 741–754.
- Shepard PJ, Hertel KJ (2009) The SR protein family. *Genome biology* 10: 242.
- Martinez-Contreras R, Cloutier P, Shkreta L, Fisette JF, Revil T, et al. (2007) hnRNP proteins and splicing control. *Advances in experimental medicine and biology* 623: 123–147.
- Buratti E, Baralle FE (2004) Influence of RNA secondary structure on the pre-mRNA splicing process. *Molecular and cellular biology* 24: 10505–10514.
- Jin Y, Yang Y, Zhang P (2011) New insights into RNA secondary structure in the alternative splicing of pre-mRNAs. *RNA biology* 8: 450–457.
- McManus CJ, Graveley BR (2011) RNA structure and the mechanisms of alternative splicing. *Current opinion in genetics & development* 21: 373–379.
- Warf MB, Berglund JA (2010) Role of RNA structure in regulating pre-mRNA splicing. *Trends in biochemical sciences* 35: 169–178.
- Lewis BP, Green RE, Brenner SE (2003) Evidence for the widespread coupling of alternative splicing and nonsense-mediated mRNA decay in humans. *Proceedings of the National Academy of Sciences of the United States of America* 100: 189–192.
- Pan Q, Saltzman AL, Kim YK, Misquitta C, Shai O, et al. (2006) Quantitative microarray profiling provides evidence against widespread coupling of alternative splicing with nonsense-mediated mRNA decay to control gene expression. *Genes & development* 20: 153–158.
- Papworth C, Bauer JC, Braman J, Wright DA (1996) Site-directed mutagenesis in one day with >80% efficiency. *Strategies* 9: 3–4.
- Wilhelm E, Pellay FX, Benecke A, Bell B (2008) Determining the impact of alternative splicing events on transcriptome dynamics. *BMC Res Notes* 1: 94.
- Noth S, Brysbaert G, Pellay FX, Benecke A (2006) High-sensitivity transcriptome data structure and implications for analysis and biologic interpretation. *Genomics Proteomics Bioinformatics* 4: 212–229.
- Brysbaert G, Pellay FX, Noth S, Benecke A (2010) Quality assessment of transcriptome data using intrinsic statistical properties. *Genomics, proteomics & bioinformatics* 8: 57–71.
- Noth S, Brysbaert G, Benecke A (2006) Normalization using weighted negative second order exponential error functions (NeONORM) provides robustness against asymmetries in comparative transcriptome profiles and avoids false calls. *Genomics Proteomics Bioinformatics* 4: 90–109.
- Rasmussen AL, Tchitchek N, Susnow NJ, Krasnoselsky AL, Diamond DL, et al. (2012) Early transcriptional programming links progression to hepatitis C virus-induced severe liver disease in transplant patients. *Hepatology* 56: 17–27.
- Tchitchek N, Dzib JF, Targat B, Noth S, Benecke A, et al. (2012) CDS: a fold-change based statistical test for concomitant identification of distinctness and similarity in gene expression analysis. *Genomics, proteomics & bioinformatics* 10: 127–135.
- Michel B, Komarnitsky P, Buratowski S (1998) Histone-like TAFs are essential for transcription in vivo. *Mol Cell* 2: 663–673.
- Shen WC, Bhaumik SR, Causton HC, Simon I, Zhu X, et al. (2003) Systematic analysis of essential yeast TAFs in genome-wide transcription and preinitiation complex assembly. *Embo J* 22: 3395–3402.
- Aoyagi N, Wassarman DA (2001) Developmental and transcriptional consequences of mutations in *Drosophila* TAF(II)60. *Mol Cell Biol* 21: 6808–6819.
- Amsterdam A, Nissen RM, Sun Z, Swindell EC, Farrington S, et al. (2004) Identification of 315 genes essential for early zebrafish development. *Proc Natl Acad Sci U S A* 101: 12792–12797.
- Noth S, Benecke A (2005) Avoiding inconsistencies over time and tracking difficulties in Applied Biosystems AB1700/Panther probe-to-gene annotations. *BMC Bioinformatics* 6: 307.
- Fairbrother WG, Yeo GW, Yeh R, Goldstein P, Mawson M, et al. (2004) RESCUE-ESE identifies candidate exonic splicing enhancers in vertebrate exons. *Nucleic acids research* 32: W187–190.
- Cartegni L, Wang J, Zhu Z, Zhang MQ, Krainer AR (2003) ESEfinder: A web resource to identify exonic splicing enhancers. *Nucleic Acids Res* 31: 3568–3571.
- Stamm S, Riethoven JJ, Le Texier V, Gopalakrishnan C, Kumanduri V, et al. (2006) ASD: a bioinformatics resource on alternative splicing. *Nucleic acids research* 34: D46–55.

36. Gao K, Masuda A, Matsuura T, Ohno K (2008) Human branch point consensus sequence is γ UnAy. *Nucleic acids research* 36: 2257–2267.
37. Expert-Bezancon A, Le Caer JP, Marie J (2002) Heterogeneous nuclear ribonucleoprotein (hnRNP) K is a component of an intronic splicing enhancer complex that activates the splicing of the alternative exon 6A from chicken beta-tropomyosin pre-mRNA. *The Journal of biological chemistry* 277: 16614–16623.
38. Sirand-Pugnet P, Durosay P, Brody E, Marie J (1995) An intronic (A/U)GGG repeat enhances the splicing of an alternative intron of the chicken beta-tropomyosin pre-mRNA. *Nucleic acids research* 23: 3501–3507.
39. Yang X, Bani MR, Lu SJ, Rowan S, Ben-David Y, et al. (1994) The A1 and A1B proteins of heterogeneous nuclear ribonucleoproteins modulate 5' splice site selection in vivo. *Proceedings of the National Academy of Sciences of the United States of America* 91: 6924–6928.
40. Ishikawa F, Matunis MJ, Dreyfuss G, Cech TR (1993) Nuclear proteins that bind the pre-mRNA 3' splice site sequence r(UUAG/G) and the human telomeric DNA sequence d(TTAGGG)n. *Molecular and cellular biology* 13: 4301–4310.
41. Roca X, Krainer AR, Eperon IC (2013) Pick one, but be quick: 5' splice sites and the problems of too many choices. *Genes & development* 27: 129–144.
42. Zuker M (2003) Mfold web server for nucleic acid folding and hybridization prediction. *Nucleic acids research* 31: 3406–3415.
43. Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, et al. (1998) Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. *Nature* 393: 702–705.
44. Poon D, Bai Y, Campbell AM, Bjorklund S, Kim YJ, et al. (1995) Identification and characterization of a TFIID-like multiprotein complex from *Saccharomyces cerevisiae*. *Proc Natl Acad Sci U S A* 92: 8224–8228.
45. Reed JC (2002) Apoptosis-based therapies. *Nat Rev Drug Discov* 1: 111–121.
46. Ranger AM, Malynn BA, Korsmeyer SJ (2001) Mouse models of cell death. *Nat Genet* 28: 113–118.
47. Vogelstein B, Kinzler KW (2004) Cancer genes and the pathways they control. *Nat Med* 10: 789–799.
48. Watson J (2013) Oxidants, antioxidants and the current incurability of metastatic cancers. *Open biology* 3: 120144.
49. Kar A, Fushimi K, Zhou X, Ray P, Shi C, et al. (2011) RNA helicase p68 (DDX5) regulates tau exon 10 splicing by modulating a stem-loop structure at the 5' splice site. *Molecular and cellular biology* 31: 1812–1821.
50. Moore MJ, Wang Q, Kennedy CJ, Silver PA (2010) An alternative splicing network links cell-cycle control to apoptosis. *Cell* 142: 625–636.
51. Wan D, Gong Y, Qin W, Zhang P, Li J, et al. (2004) Large-scale cDNA transfection screening for genes related to cancer development and progression. *Proc Natl Acad Sci U S A* 101: 15724–15729.
52. Campbell JM, Lockwood WW, Buys TP, Chari R, Coe BP, et al. (2008) Integrative genomic and gene expression analysis of chromosome 7 identified novel oncogene loci in non-small cell lung cancer. *Genome* 51: 1032–1039.
53. Aviel-Ronen S, Coe BP, Lau SK, da Cunha Santos G, Zhu CQ, et al. (2008) Genomic markers for malignant progression in pulmonary adenocarcinoma with bronchioloalveolar features. *Proc Natl Acad Sci U S A* 105: 10155–10160.
54. Dressman HK, Hans C, Bild A, Olson JA, Rosen E, et al. (2006) Gene expression profiles of multiple breast cancer phenotypes and response to neoadjuvant chemotherapy. *Clin Cancer Res* 12: 819–826.
55. Wang W, Nahta R, Huper G, Marks JR (2004) TAFII70 isoform-specific growth suppression correlates with its ability to complex with the GADD45a protein. *Mol Cancer Res* 2: 442–452.